Beigene/Boehringer Biomanufacturing Bond Tests China MAH System

Nasdaq-listed BeiGene expects to need more CMO services for its clinical stage biologics following on from a clinical trials manufacturing agreement for a PD-1 antibody with Boehringer Ingelheim China, which marked the first such pilot program under China’s drug marketing authorization holder system. Shanghai is also preparing risk guarantee funds to back the pilot program, in order to promote pharmaceutical innovation.

SHANGHAI - With the support of the government, Boehringer Ingelheim GMBH‘s China Biopharmaceuticals site has kicked off its first trial contract manufacturing organization (CMO) project, for an oncology drug developed byBeiGene (Beijing) Co. Ltd.

Newly US Nasdaq-listed BeiGene will consider expanding its cooperation with the site for other biopharmaceutical products. “The first trial product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia